$0.016
0[0.00%]
At close: Sep 29
Infinity Pharmaceuticals Inc
(OTC:INFI)Infinity Pharmaceuticals Inc Stock (OTC:INFI), Analyst Ratings, Price Targets, Predictions
Infinity Pharmaceuticals Inc has a consensus price target of $5.75, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, B. Riley Securities, and Piper Sandler on February 24, 2023, November 16, 2022, and May 23, 2022. With an average price target of $1.5 between Piper Sandler, B. Riley Securities, and Piper Sandler, there's an implied 9275.00% upside for Infinity Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
B. Riley Securities
Truist Securities
HC Wainwright & Co.
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Infinity Pharmaceuticals Inc
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/24/2023 | INFI | Buy Now | Infinity Pharmaceuticals | $0.02 | — | Piper Sandler | Edward Tenthoff | — | Downgrade | Overweight → Neutral | Get Alert |
| 11/16/2022 | INFI | Buy Now | Infinity Pharmaceuticals | $0.02 | 9275% | B. Riley Securities | Kalpit Patel | $3 → $1.5 | Downgrade | Buy → Neutral | Get Alert |
| 05/23/2022 | INFI | Buy Now | Infinity Pharmaceuticals | $0.02 | 18650% | Piper Sandler | Edward Tenthoff | $4 → $3 | Maintains | Overweight | Get Alert |
| 03/31/2022 | INFI | Buy Now | Infinity Pharmaceuticals | $0.02 | 24900% | Truist Securities | Robyn Karnauskas | $12 → $4 | Maintains | Buy | Get Alert |
| 03/30/2022 | INFI | Buy Now | Infinity Pharmaceuticals | $0.02 | 24900% | Piper Sandler | Edward Tenthoff | $8 → $4 | Maintains | Overweight | Get Alert |
| 10/18/2021 | INFI | Buy Now | Infinity Pharmaceuticals | $0.02 | 56150% | HC Wainwright & Co. | Michael King | — | Initiates | → Buy | Get Alert |
| 08/02/2021 | INFI | Buy Now | Infinity Pharmaceuticals | $0.02 | 37400% | JP Morgan | Anupam Rama | — | Upgrade | Neutral → Overweight | Get Alert |
| 07/28/2021 | INFI | Buy Now | Infinity Pharmaceuticals | $0.02 | 87400% | Wells Fargo | — | — | Upgrade | Equal-Weight → Overweight | Get Alert |
FAQ
What is the target price for Infinity Pharmaceuticals Inc (INFI)?
The latest price target for Infinity Pharmaceuticals Inc (OTC: INFI) was reported by Piper Sandler on February 24, 2023. The analyst firm set a price target for $0.00 expecting INFI to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Infinity Pharmaceuticals Inc (INFI)?
The latest analyst rating for Infinity Pharmaceuticals Inc (OTC: INFI) was provided by Piper Sandler, and Infinity Pharmaceuticals Inc downgraded their neutral rating.
When was the last upgrade for Infinity Pharmaceuticals Inc (INFI)?
The last upgrade for Infinity Pharmaceuticals Inc happened on August 2, 2021 when JP Morgan raised their price target to $6. JP Morgan previously had a neutral for Infinity Pharmaceuticals Inc.
When was the last downgrade for Infinity Pharmaceuticals Inc (INFI)?
The last downgrade for Infinity Pharmaceuticals Inc happened on February 24, 2023 when Piper Sandler changed their price target from N/A to N/A for Infinity Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Infinity Pharmaceuticals Inc (INFI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Infinity Pharmaceuticals Inc, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Infinity Pharmaceuticals Inc was filed on February 24, 2023 so you should expect the next rating to be made available sometime around February 24, 2024.
Is the Analyst Rating Infinity Pharmaceuticals Inc (INFI) correct?
While ratings are subjective and will change, the latest Infinity Pharmaceuticals Inc (INFI) rating was a downgraded with a price target of $0.00 to $0.00. The current price Infinity Pharmaceuticals Inc (INFI) is trading at is $0.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.